| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 61 | 2023 | 1271 | 8.720 |
Why?
|
| Tissue and Organ Procurement | 19 | 2023 | 311 | 5.040 |
Why?
|
| Kidney Transplantation | 21 | 2024 | 849 | 4.480 |
Why?
|
| Tissue Donors | 22 | 2023 | 464 | 3.730 |
Why?
|
| Graft Survival | 36 | 2024 | 885 | 3.530 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 509 | 1.740 |
Why?
|
| Graft Rejection | 15 | 2019 | 1065 | 1.570 |
Why?
|
| Waiting Lists | 10 | 2023 | 175 | 1.530 |
Why?
|
| Liver Failure | 7 | 2023 | 79 | 1.490 |
Why?
|
| Hepatitis C | 7 | 2019 | 210 | 1.310 |
Why?
|
| End Stage Liver Disease | 3 | 2023 | 62 | 1.200 |
Why?
|
| Liver Diseases | 6 | 2020 | 241 | 1.180 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2012 | 386 | 1.140 |
Why?
|
| Living Donors | 8 | 2023 | 339 | 1.140 |
Why?
|
| Liver Cirrhosis | 5 | 2014 | 300 | 1.080 |
Why?
|
| Survival Rate | 19 | 2020 | 1864 | 1.010 |
Why?
|
| Kidney | 5 | 2023 | 1242 | 1.000 |
Why?
|
| Retrospective Studies | 36 | 2024 | 8496 | 1.000 |
Why?
|
| Liver Neoplasms | 6 | 2012 | 738 | 0.990 |
Why?
|
| Liver Failure, Acute | 3 | 2009 | 38 | 0.900 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2013 | 295 | 0.840 |
Why?
|
| Death | 6 | 2020 | 73 | 0.830 |
Why?
|
| Humans | 86 | 2024 | 86678 | 0.810 |
Why?
|
| Liver | 10 | 2021 | 1230 | 0.770 |
Why?
|
| Risk Factors | 18 | 2024 | 5420 | 0.710 |
Why?
|
| Risk Assessment | 11 | 2020 | 2264 | 0.710 |
Why?
|
| Postoperative Complications | 7 | 2012 | 2207 | 0.690 |
Why?
|
| Forkhead Transcription Factors | 3 | 2013 | 166 | 0.670 |
Why?
|
| Portal Vein | 3 | 2010 | 120 | 0.670 |
Why?
|
| Transplantation, Homologous | 8 | 2010 | 996 | 0.670 |
Why?
|
| Liver Circulation | 2 | 2010 | 30 | 0.660 |
Why?
|
| Transplant Recipients | 1 | 2020 | 122 | 0.660 |
Why?
|
| Male | 49 | 2023 | 40988 | 0.650 |
Why?
|
| Adult | 32 | 2023 | 25659 | 0.640 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 3642 | 0.630 |
Why?
|
| Models, Statistical | 2 | 2013 | 575 | 0.610 |
Why?
|
| Obesity | 4 | 2024 | 964 | 0.610 |
Why?
|
| Female | 49 | 2023 | 44550 | 0.600 |
Why?
|
| Fatty Liver | 3 | 2010 | 125 | 0.600 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 1313 | 0.600 |
Why?
|
| Immune Tolerance | 3 | 2013 | 337 | 0.570 |
Why?
|
| Patient Selection | 6 | 2012 | 686 | 0.560 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 806 | 0.550 |
Why?
|
| Transplantation Tolerance | 2 | 2008 | 130 | 0.550 |
Why?
|
| Middle Aged | 33 | 2023 | 25040 | 0.540 |
Why?
|
| Aged | 21 | 2024 | 18423 | 0.530 |
Why?
|
| Dendritic Cells | 3 | 2013 | 425 | 0.530 |
Why?
|
| Severity of Illness Index | 9 | 2023 | 1802 | 0.530 |
Why?
|
| Donor Selection | 3 | 2020 | 68 | 0.510 |
Why?
|
| Treatment Outcome | 20 | 2024 | 7998 | 0.510 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2013 | 36 | 0.480 |
Why?
|
| Length of Stay | 3 | 2013 | 704 | 0.480 |
Why?
|
| Hepatic Artery | 3 | 2012 | 83 | 0.470 |
Why?
|
| Child, Preschool | 13 | 2020 | 3613 | 0.470 |
Why?
|
| Prognosis | 11 | 2019 | 3680 | 0.450 |
Why?
|
| Child | 16 | 2020 | 6928 | 0.450 |
Why?
|
| Adolescent | 17 | 2020 | 8984 | 0.430 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 819 | 0.430 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 365 | 0.420 |
Why?
|
| Perfusion | 2 | 2020 | 203 | 0.420 |
Why?
|
| United States | 14 | 2023 | 6681 | 0.420 |
Why?
|
| Hepacivirus | 6 | 2019 | 160 | 0.410 |
Why?
|
| Health Status Indicators | 1 | 2012 | 105 | 0.400 |
Why?
|
| Thinness | 2 | 2010 | 43 | 0.400 |
Why?
|
| Reoperation | 5 | 2023 | 597 | 0.400 |
Why?
|
| Survival Analysis | 6 | 2014 | 1538 | 0.380 |
Why?
|
| Antigens, CD | 3 | 2008 | 458 | 0.380 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2010 | 8 | 0.380 |
Why?
|
| Cause of Death | 4 | 2020 | 277 | 0.380 |
Why?
|
| Critical Care | 2 | 2020 | 370 | 0.370 |
Why?
|
| Infant | 12 | 2020 | 3047 | 0.370 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 235 | 0.360 |
Why?
|
| Drug Monitoring | 1 | 2010 | 118 | 0.350 |
Why?
|
| Adoptive Transfer | 2 | 2006 | 168 | 0.350 |
Why?
|
| Preoperative Care | 2 | 2009 | 397 | 0.350 |
Why?
|
| Acetaminophen | 2 | 2006 | 54 | 0.340 |
Why?
|
| Prospective Studies | 8 | 2018 | 4214 | 0.340 |
Why?
|
| Renal Dialysis | 2 | 2024 | 355 | 0.340 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 1001 | 0.340 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2009 | 36 | 0.330 |
Why?
|
| Body Mass Index | 4 | 2024 | 770 | 0.330 |
Why?
|
| Fatigue | 1 | 2009 | 174 | 0.330 |
Why?
|
| Constriction, Pathologic | 2 | 2006 | 213 | 0.330 |
Why?
|
| Medical Errors | 1 | 2009 | 115 | 0.320 |
Why?
|
| Young Adult | 11 | 2020 | 5980 | 0.320 |
Why?
|
| Thrombosis | 2 | 2012 | 296 | 0.320 |
Why?
|
| Time Factors | 10 | 2019 | 5214 | 0.310 |
Why?
|
| Transplants | 2 | 2018 | 40 | 0.310 |
Why?
|
| Incidence | 8 | 2019 | 1578 | 0.300 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 6513 | 0.290 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2006 | 13 | 0.290 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 8 | 0.290 |
Why?
|
| Compartment Syndromes | 1 | 2006 | 12 | 0.290 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2006 | 12 | 0.290 |
Why?
|
| Catheter Ablation | 1 | 2009 | 233 | 0.290 |
Why?
|
| Hepatitis | 1 | 2006 | 35 | 0.290 |
Why?
|
| Biliary Atresia | 1 | 2006 | 22 | 0.290 |
Why?
|
| Liver Regeneration | 1 | 2006 | 32 | 0.290 |
Why?
|
| Aprotinin | 1 | 2006 | 26 | 0.290 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.290 |
Why?
|
| Delayed Graft Function | 2 | 2020 | 12 | 0.290 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2006 | 28 | 0.290 |
Why?
|
| Bile Ducts | 1 | 2006 | 59 | 0.280 |
Why?
|
| Mannose-Binding Lectin | 1 | 2006 | 3 | 0.280 |
Why?
|
| Cholecystectomy | 1 | 2006 | 18 | 0.280 |
Why?
|
| Hemochromatosis | 1 | 2006 | 11 | 0.280 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 141 | 0.280 |
Why?
|
| Ferric Compounds | 1 | 2006 | 38 | 0.280 |
Why?
|
| Hemostatics | 1 | 2006 | 56 | 0.280 |
Why?
|
| Abdomen | 1 | 2006 | 122 | 0.270 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2006 | 50 | 0.270 |
Why?
|
| Staining and Labeling | 1 | 2006 | 165 | 0.270 |
Why?
|
| Brain Death | 5 | 2020 | 69 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 107 | 0.270 |
Why?
|
| Ascites | 1 | 2006 | 56 | 0.270 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 139 | 0.270 |
Why?
|
| Exercise Therapy | 1 | 2006 | 80 | 0.270 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2006 | 52 | 0.270 |
Why?
|
| Quality of Health Care | 2 | 2006 | 381 | 0.270 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 94 | 0.270 |
Why?
|
| Hepatitis B | 1 | 2006 | 74 | 0.260 |
Why?
|
| Albumins | 1 | 2006 | 133 | 0.260 |
Why?
|
| Immune System | 1 | 2006 | 93 | 0.260 |
Why?
|
| Herniorrhaphy | 1 | 2006 | 79 | 0.260 |
Why?
|
| Steroids | 1 | 2006 | 177 | 0.260 |
Why?
|
| Surgical Mesh | 1 | 2006 | 116 | 0.260 |
Why?
|
| Hepatocytes | 1 | 2006 | 127 | 0.260 |
Why?
|
| Th2 Cells | 1 | 2006 | 146 | 0.260 |
Why?
|
| Serotonin | 1 | 2006 | 218 | 0.260 |
Why?
|
| Vascular Diseases | 1 | 2006 | 121 | 0.250 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 144 | 0.250 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 142 | 0.250 |
Why?
|
| HLA Antigens | 1 | 2006 | 232 | 0.250 |
Why?
|
| Bacterial Infections | 1 | 2006 | 182 | 0.240 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 435 | 0.240 |
Why?
|
| Palliative Care | 1 | 2006 | 257 | 0.240 |
Why?
|
| Stents | 1 | 2006 | 377 | 0.240 |
Why?
|
| Critical Illness | 1 | 2006 | 294 | 0.230 |
Why?
|
| Liver Function Tests | 4 | 2010 | 93 | 0.230 |
Why?
|
| Body Surface Area | 1 | 2023 | 36 | 0.230 |
Why?
|
| Intention to Treat Analysis | 1 | 2023 | 72 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2006 | 409 | 0.220 |
Why?
|
| Organ Transplantation | 1 | 2006 | 265 | 0.220 |
Why?
|
| Mice, Inbred C3H | 3 | 2008 | 370 | 0.220 |
Why?
|
| Immunosuppressive Agents | 3 | 2010 | 977 | 0.220 |
Why?
|
| Infant, Newborn | 5 | 2020 | 2379 | 0.210 |
Why?
|
| Policy | 1 | 2022 | 34 | 0.210 |
Why?
|
| Cohort Studies | 7 | 2020 | 2768 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2601 | 0.210 |
Why?
|
| Proteome | 2 | 2014 | 124 | 0.210 |
Why?
|
| Geography | 1 | 2022 | 223 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 860 | 0.200 |
Why?
|
| Insulin | 1 | 2006 | 1160 | 0.190 |
Why?
|
| Health Policy | 1 | 2022 | 180 | 0.190 |
Why?
|
| Social Class | 1 | 2020 | 128 | 0.180 |
Why?
|
| Databases, Factual | 4 | 2019 | 816 | 0.180 |
Why?
|
| Cold Ischemia | 3 | 2010 | 17 | 0.180 |
Why?
|
| Mice | 7 | 2013 | 11356 | 0.180 |
Why?
|
| Insurance, Health | 1 | 2020 | 160 | 0.180 |
Why?
|
| Terminal Care | 1 | 2020 | 130 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2006 | 754 | 0.170 |
Why?
|
| Body Weight | 3 | 2010 | 459 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2020 | 170 | 0.160 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 8 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 2271 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 1673 | 0.160 |
Why?
|
| Tacrolimus | 2 | 2010 | 373 | 0.160 |
Why?
|
| Quality Control | 1 | 2018 | 117 | 0.160 |
Why?
|
| Medicaid | 1 | 2020 | 217 | 0.160 |
Why?
|
| Animals | 9 | 2013 | 26590 | 0.160 |
Why?
|
| Blood Flow Velocity | 2 | 2010 | 197 | 0.160 |
Why?
|
| Hypertension | 1 | 2006 | 1142 | 0.160 |
Why?
|
| Antilymphocyte Serum | 1 | 1997 | 71 | 0.150 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 69 | 0.150 |
Why?
|
| Histocompatibility Testing | 2 | 2008 | 154 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 60 | 0.150 |
Why?
|
| Logistic Models | 3 | 2010 | 1188 | 0.150 |
Why?
|
| CTLA-4 Antigen | 2 | 2008 | 135 | 0.150 |
Why?
|
| Probability | 2 | 2009 | 355 | 0.150 |
Why?
|
| Intestines | 2 | 2010 | 411 | 0.140 |
Why?
|
| Cell Transplantation | 2 | 2006 | 47 | 0.140 |
Why?
|
| Needs Assessment | 2 | 2009 | 154 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 372 | 0.140 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 307 | 0.140 |
Why?
|
| Glucose Tolerance Test | 2 | 2006 | 228 | 0.140 |
Why?
|
| Age Factors | 5 | 2018 | 1852 | 0.130 |
Why?
|
| Proteomics | 2 | 2014 | 211 | 0.130 |
Why?
|
| Registries | 3 | 2010 | 703 | 0.120 |
Why?
|
| Washington | 2 | 2012 | 48 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1807 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2013 | 83 | 0.110 |
Why?
|
| Cyclosporine | 2 | 2008 | 234 | 0.110 |
Why?
|
| Methylprednisolone | 2 | 2006 | 66 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 861 | 0.110 |
Why?
|
| Decision Making | 1 | 2018 | 642 | 0.110 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 50 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 2 | 2006 | 144 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 250 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 3095 | 0.100 |
Why?
|
| Heart Transplantation | 2 | 2006 | 705 | 0.100 |
Why?
|
| Medical Futility | 1 | 2010 | 28 | 0.090 |
Why?
|
| RNA, Viral | 2 | 2010 | 329 | 0.090 |
Why?
|
| Intraoperative Period | 1 | 2010 | 90 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 111 | 0.090 |
Why?
|
| Gastroschisis | 1 | 2010 | 13 | 0.090 |
Why?
|
| Reperfusion | 1 | 2010 | 31 | 0.090 |
Why?
|
| Intestinal Volvulus | 1 | 2010 | 10 | 0.090 |
Why?
|
| Transplantation | 1 | 2010 | 39 | 0.090 |
Why?
|
| Short Bowel Syndrome | 1 | 2010 | 37 | 0.090 |
Why?
|
| Bilirubin | 1 | 2009 | 125 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2010 | 265 | 0.090 |
Why?
|
| Intestinal Diseases | 1 | 2010 | 79 | 0.090 |
Why?
|
| Allografts | 2 | 2020 | 172 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 126 | 0.080 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2010 | 78 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 44 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2006 | 512 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 79 | 0.080 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 54 | 0.080 |
Why?
|
| Bile Duct Diseases | 1 | 2008 | 22 | 0.080 |
Why?
|
| Workload | 1 | 2009 | 128 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 199 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 185 | 0.080 |
Why?
|
| Interleukin-4 | 1 | 2008 | 127 | 0.080 |
Why?
|
| Quality of Life | 2 | 2006 | 1585 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 455 | 0.080 |
Why?
|
| ROC Curve | 1 | 2010 | 752 | 0.080 |
Why?
|
| Risk | 3 | 2019 | 674 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2008 | 219 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2006 | 18 | 0.070 |
Why?
|
| Mice, Obese | 1 | 2006 | 44 | 0.070 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 60 | 0.070 |
Why?
|
| Warm Ischemia | 1 | 2006 | 28 | 0.070 |
Why?
|
| Bezafibrate | 1 | 2006 | 5 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 81 | 0.070 |
Why?
|
| Hepatic Encephalopathy | 1 | 2006 | 42 | 0.070 |
Why?
|
| Polypropylenes | 1 | 2006 | 23 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2006 | 20 | 0.070 |
Why?
|
| Microcirculation | 1 | 2006 | 106 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 159 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 76 | 0.070 |
Why?
|
| Homozygote | 1 | 2006 | 200 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 197 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1753 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 48 | 0.070 |
Why?
|
| Leptin | 1 | 2006 | 105 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 301 | 0.070 |
Why?
|
| Restriction Mapping | 1 | 2006 | 157 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 1195 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 42 | 0.070 |
Why?
|
| Chimera | 1 | 2006 | 56 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 482 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 96 | 0.070 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2006 | 40 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2006 | 149 | 0.070 |
Why?
|
| Psychology | 1 | 2005 | 24 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 1 | 2006 | 114 | 0.070 |
Why?
|
| Cricetinae | 1 | 2006 | 560 | 0.070 |
Why?
|
| Organ Preservation | 1 | 2006 | 83 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2006 | 229 | 0.070 |
Why?
|
| Heterozygote | 1 | 2006 | 365 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 715 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 102 | 0.070 |
Why?
|
| Spleen | 1 | 2006 | 430 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2006 | 252 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2006 | 61 | 0.070 |
Why?
|
| Linear Models | 1 | 2006 | 422 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 131 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 154 | 0.060 |
Why?
|
| Drug Overdose | 1 | 2006 | 65 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 430 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 318 | 0.060 |
Why?
|
| Diarrhea | 1 | 2006 | 182 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 107 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 267 | 0.060 |
Why?
|
| Suicide, Attempted | 1 | 2006 | 129 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 331 | 0.060 |
Why?
|
| Monocytes | 1 | 2006 | 216 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 363 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 161 | 0.060 |
Why?
|
| Catheterization | 1 | 2006 | 232 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 241 | 0.060 |
Why?
|
| Haplotypes | 1 | 2006 | 642 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2005 | 221 | 0.060 |
Why?
|
| Biomarkers | 1 | 2010 | 1718 | 0.060 |
Why?
|
| Species Specificity | 1 | 2006 | 678 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 916 | 0.060 |
Why?
|
| Gene Expression | 1 | 2008 | 1284 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 813 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 339 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 425 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2006 | 377 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2010 | 1351 | 0.060 |
Why?
|
| Alleles | 1 | 2006 | 1128 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2006 | 374 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 105 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 189 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 865 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 778 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2006 | 373 | 0.050 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 2001 | 9 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1683 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 462 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 334 | 0.050 |
Why?
|
| Recurrence | 3 | 2012 | 1139 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2819 | 0.050 |
Why?
|
| Biopsy | 2 | 2010 | 1163 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1376 | 0.050 |
Why?
|
| Advance Care Planning | 1 | 2020 | 43 | 0.050 |
Why?
|
| Shock | 1 | 2020 | 43 | 0.050 |
Why?
|
| Rats | 1 | 2006 | 3992 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1458 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 232 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2231 | 0.040 |
Why?
|
| Cadaver | 1 | 2019 | 185 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2001 | 243 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 23 | 0.040 |
Why?
|
| Plasma | 1 | 2018 | 50 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 2357 | 0.040 |
Why?
|
| Acyclovir | 1 | 1997 | 107 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3362 | 0.040 |
Why?
|
| Azathioprine | 1 | 1997 | 125 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 1532 | 0.030 |
Why?
|
| Acute Disease | 1 | 1997 | 826 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1997 | 352 | 0.030 |
Why?
|
| Mutation | 1 | 2006 | 3968 | 0.030 |
Why?
|
| Ions | 1 | 2014 | 74 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2012 | 70 | 0.030 |
Why?
|
| Thrombophilia | 1 | 2012 | 22 | 0.030 |
Why?
|
| Models, Animal | 1 | 2013 | 263 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 107 | 0.030 |
Why?
|
| Reference Values | 1 | 2012 | 674 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 25 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 268 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 308 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 364 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 332 | 0.020 |
Why?
|
| Genotype | 2 | 2008 | 1852 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2010 | 83 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 196 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 448 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 12 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2008 | 63 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 124 | 0.020 |
Why?
|
| Overweight | 1 | 2009 | 118 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 177 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1992 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1055 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2010 | 533 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1513 | 0.020 |
Why?
|
| Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1997 | 1204 | 0.010 |
Why?
|